Roche has halted development on…
Roche has halted development on two of its Huntington’s disease [...]
“We were not expecting to see…
“We were not expecting to see clinical responses so early,” [...]
GSK has walked away from a $2.2…
GSK has walked away from a $2.2 billion biobucks neurodegenerative [...]
The FDA has paused a controversial…
The FDA has paused a controversial policy of releasing letters [...]
Prime Medicine has come out ahead…
Prime Medicine has come out ahead in its patent dispute [...]
Satellos Bioscience has shared…
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy [...]
AstraZeneca is paying Sino…
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China [...]
As MeiraGTx lines up the pieces…
As MeiraGTx lines up the pieces for a commercial push, [...]
Biocytogen and Whitehawk…
Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific [...]
Novartis is pushing deeper into…
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 [...]